EvoGenix to list on ASX in August
29 June, 2005 by Ruth BeranAntibody therapeutics company EvoGenix will open its initial public offering within a week and list on the ASX in early to mid-August, with the aim of raising AUD$9 million.
In brief: CSL, Progen Industries, Mayne Group
28 June, 2005 by Ruth BeranCSL (ASX:CSL) will be conducting a further on-market buyback of up to 8 million shares during a 12-month period commencing July 12.
FDA approves first 'ethnic medicine'
28 June, 2005 by Kevin DaviesThe FDA, as expected, has followed the recommendation of an advisory panel last week and approved the heart drug BiDil, which clinical data have shown works well in African-Americans but poorly in other populations.
Medical Developments share price boosted by Penthrox trial
28 June, 2005 by Ruth BeranMelbourne based Medical Developments International (ASX:MVP) believes the launch of its Penthrox Inhaler into the Australian dentistry market caused a share price rise from $0.745 on June 24, to $0.87 on June 27, prompting the ASX to issue the company with a 'speeding ticket'.
In brief: ChemGenex Pharmaceuticals, Novogen, Peptech
27 June, 2005 by Ruth BeranChemGenex Pharmaceuticals (ASX:CXS) has received approval to list on the NASDAQ SmallCap Market under the ticker CXSP.
EU ministers uphold sovereign right to ban GMOs
27 June, 2005 by Ruth BeranEU environment ministers dealt a blow to efforts to get more GMO crops grown in Europe as they agreed to uphold eight national bans on genetically modified maize and rapeseed types.
Ai Scientific secures major Italian order
27 June, 2005 by Ruth BeranBrisbane-based clinical automation systems manufacturer, Ai Scientific, has secured a multi-million dollar order from Italian distributor, Medical Systems.
Visiomed begins clinical evaluation trials
27 June, 2005 by Susan WilliamsonPerth-based biomedical devices developer, Visiomed Group (ASX:VSG) and ophthalmic surgical laser group, CustomVis (AIM:CUS), also based in Perth, have begun a clinical evaluation trial on their ophthalmic imaging system, microEYE.
In brief: Pharmanet Group, Metabolic Pharmaceuticals, Genetic Technologies
24 June, 2005 by Ruth BeranThe sale of Pharmanet Group's (ASX:PNO) wholly owned subsidiary Medical Products Group, to Advance Healthcare (ASX:AHG), has been completed.
In brief: Pharmaxis, Metabolic, Avantogen, Biotech Capital, Bone Medical, Xceed Biotechnology
23 June, 2005 by Ruth BeranPharmaxis (ASX:PXS) has responded to a request by the ASX to explain why its shares rose from $1.34 on 15 June 2005 to $1.61 on 22 June 2005 by saying that it is unaware of any information that could explain the price change and increase in volume of trading in its shares over that period.
Avastra clinical trial halted
23 June, 2005 by Ruth BeranSydney biomaterials company Avastra (ASX:AVS) has halted its Bioweld human clinical trial due to unexpected results in its long-term animal study, although the company is still unsure what caused the unexpected results.
Low-glycaemic index barley proves healthy alternative
22 June, 2005 by Graeme O'NeillCSIRO Plant Industry released its new low-glyceaemic index barley last week: BARLEYMax, developed from a mutant form of an old 'lab rat' strain of barley called Himalaya.
Bionomics discovers breast cancer diagnostic
22 June, 2005 by Ruth BeranSouth Australian genomics company Bionomics (ASX:BNO) has found that antibodies against it's proprietary cancer drug target BNO69 can be used to distinguish between malignant and benign breast cancers.
Independent clinical study for Solagran's Bioeffective R
21 June, 2005 by Ruth BeranThe Centre for Neuropsychology at Swinburne University of Technology will conduct an independent study, subject to ethical approval, for botanical biotech Solagran (ASX:SLA) to examine the neuro-cognitive, mood and brain EEG effects of Bioeffective R.
Biota rejects offer to drop lawsuit
21 June, 2005 by Graeme O'NeillMelbourne respiratory drug developer Biota Holdings (ASX:BTA) has reportedly rejected a confidential AUD$10 million offer from GlaxoSmithKline (GSK) to drop its lawsuit seeking compensation for loss of royalties from the Australian-developed influenza drug Relenza.
